Invention Grant
- Patent Title: Multi-indication mRNA cancer immunotherapy
-
Application No.: US15583599Application Date: 2017-05-01
-
Publication No.: US10682401B2Publication Date: 2020-06-16
- Inventor: Michael J. P. Lawman , Patricia D. Lawman , Meghan Gentilini , Vijay Ramiya , Marina Victor Abdelmaseeh Bastawrous , Michael J. Shamblott
- Applicant: MORPHOGENESIS, INC.
- Applicant Address: US FL Tampa
- Assignee: MORPHOGENESIS, INC.
- Current Assignee: MORPHOGENESIS, INC.
- Current Assignee Address: US FL Tampa
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Main IPC: C07H21/04
- IPC: C07H21/04 ; A61K31/70 ; A61K48/00 ; A61K39/00 ; A61K45/06 ; A61K39/09 ; A01K67/00

Abstract:
Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
Public/Granted literature
- US20170232090A1 MULTI-INDICATION MRNA CANCER IMMUNOTHERAPY Public/Granted day:2017-08-17
Information query